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Glycosylation of Trypanosoma cruzi 
tci antigen reveals recognition 
by chagasic sera
niamh Murphy1,7*, Barrie Rooney2,3,7, Tapan Bhattacharyya1, Omar Triana‑Chavez4, 
Anja Krueger5, Stuart M. Haslam5, Victoria O’Rourke1, Magdalena Pańczuk1, Jemima Tsang1, 
Jack Bickford‑Smith1, Robert H. Gilman6, Kevin Tetteh1, Chris Drakeley1, C. Mark Smales2 & 
Michael A. Miles1
Chagas disease is considered the most important parasitic disease in Latin America. The protozoan 
agent, Trypanosoma cruzi, comprises six genetic lineages, TcI‑TcVI. Genotyping to link lineage(s) 
to severity of cardiomyopathy and gastrointestinal pathology is impeded by the sequestration and 
replication of T. cruzi in host tissues. We describe serology specific for TcI, the predominant lineage 
north of the Amazon, based on expression of recombinant trypomastigote small surface antigen 
(gTSSA‑I) in the eukaryote Leishmania tarentolae, to allow realistic glycosylation and structure of the 
antigen. Sera from TcI‑endemic regions recognised gTSSA‑I (74/146; 50.7%), with no cross reaction 
with common components of gTSSA‑II/V/VI recombinant antigen. Antigenicity was abolished by 
chemical (periodate) oxidation of gTSSA‑I glycosylation but retained after heat‑denaturation of 
conformation. Conversely, non‑specific recognition of gTSSA‑I by non‑endemic malaria sera was 
abolished by heat‑denaturation. TcI‑specific serology facilitates investigation between lineage 
and diverse clinical presentations. Glycosylation cannot be ignored in the search for immunogenic 
antigens.
American trypanosomiasis (Chagas disease) is a neglected tropical disease caused by the protozoan parasite 
Trypanosoma cruzi, and is considered the most important human parasitic infection in Latin America. The 
infection is transmitted by blood sucking triatomine bugs through contamination of human mucous membranes, 
abraded skin or food, with T. cruzi infected triatomine faeces. Once acquired, unless successfully treated, T. cruzi 
usually persists as a life-long infection, which can also be transmitted congenitally from mother-to-child, and 
by transfusion or organ donation. Principal human tissues damaged are the heart and the intestinal tract, and 
symptoms may develop years after the early infection. An estimated 30% of T. cruzi infected individuals develop 
chagasic cardiomyopathy and a proportion of those develop chagasic gastrointestinal  megasyndromes1. Only 
two drugs are currently available for treatment, benznidazole and nifurtimox. Due to severe dermatological 
side effects, treatment of adults frequently fails; a shorter, lower dose schedule for benznidazole and a paediatric 
formulation have recently been  introduced2,3.
Currently WHO estimates 5–6 million cases of T. cruzi infection  worldwide4. Despite international control 
programmes, there is still a high prevalence and incidence in regions such as the Gran Chaco of Bolivia and 
Argentina. Triatomine vectors are spreading into periurban sites, and Chagas disease is becoming a global health 
issue among Latin American migrant populations, with an estimated 250,000 infected in the USA, more than 
100,000 in Europe and 12,000 in the UK, with risk of global non-vector borne transmission, congenitally and 
via blood and organ  donors5,6.
Trypanosoma cruzi comprises six genetic lineages TcI-TcVI7–9, with TcBat proposed as a seventh lineage 
related to  TcI10. Based on genotyping, TcI is the predominant agent of Chagas disease north of the Amazon, with 
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TcIV a secondary cause in  Venezuela11. TcII, TcV and TcVI are prevalent among cases in the Southern Cone 
countries of South America (Argentina, Bolivia, Brazil, Chile, Paraguay and Uruguay); TcIII is uncommonly 
found in human  infections1.
In  198112 it was proposed that the different geographical distributions of the T. cruzi lineages may contribute 
to the disparate clinical presentations of Chagas disease in the Southern Cone countries, where megasyndromes 
are found, compared to northern South America, where they are not  reported1. However, it is complex to prove 
such an association by parasite genotyping, because T. cruzi blood parasitaemia is scanty in chronic Chagas dis-
ease, does not necessarily represent lineages sequestered in the internal  organs13–16, and growth rate competition 
occurs between isolates grown in vitro.
One approach to surveillance of clinical, geographical and ecological distributions of the T. cruzi lineages is 
to develop lineage-specific serology, originally proposed by Di Noia et al.17. Specific epitopes of the T. cruzi try-
pomastigote small surface antigen (TSSA), a cell surface mucin, have been identified for all six genetic lineages, 
with the hybrid lineages TcV and TcVI having two epitopes encoded at the heterozygous locus, one of which is 
shared with TcII, as shown by Bhattacharyya et al.18. Lineage-specific serology with synthetic peptides represent-
ing the TcII/V/VI and TcV/VI epitopes enabled surveillance of chagasic  patients19, and the discovery of reservoir 
 hosts20,21. Furthermore, TcII/V/VI serology, adaptable to rapid diagnostic test (RDT) format, demonstrated that 
among Bolivian patients stratified by severity of cardiomyopathy, TcII/V/VI seropositives were five-fold more 
prevalent in the severe versus no evidence of cardiomyopathy  groups22. RDTs also identified TcII/V/VI seroposi-
tive sympatric humans and dogs in the Argentine  Chaco23.
A long-standing research objective is the validation of a robust and sensitive TcI-specific antigen that would 
enable the enigma of link between infective lineage and clinical prognosis to be more comprehensively investi-
gated. Furthermore, this would enable systematic low-cost analysis of T. cruzi transmission cycles and evaluation 
of the risk of emergence of sylvatic lineages into the domestic environment. However, repeated attempts have 
failed to develop a lineage-specific serological test for the TcI specific epitope, either using an E. coli-expressed 
recombinant protein or a synthetic  peptide19,24–26.
Here, we have expressed the TSSA-I epitope within a related trypanosomatid, Leishmania tarentolae, which 
enables O-linked and N-linked  glycosylation27,28 to determine whether glycosylation and/or structural integrity 
impart serological recognition of this TcI antigen.
Methods
Ethics. All human sera used here were archived, with consent for research, were anonymised, coded, and did 
not reveal patient identities. Informed consent was obtained from all subjects or, if subjects are under 18, consent 
was provided by a parent and/or legal guardian. No samples were collected specifically for this work.
Colombian (Bogotá), Venezuelan and Ecuadorean samples: these were collected as part of routine diagnostic 
examination, with local institutional ethical approvals Universidad de los Andes, Bogotá, Colombia; (Instituto 
de Medicina Tropical, Caracas, Venezuela; Pontificia Universidad Católica del Ecuador, Quito, Ecuador) and in 
accord with EC ethical standards, established as part of the ChagasEpiNet international collaboration (ethical 
approval from London School of Hygiene and Tropical Medicine, UK). Colombian (Medellín) ethical approval 
was provided by the Instituto de Biología, Universidad de Antioquia, Medellín, Colombia.
Peruvian and Bolivian samples: the following institutional review boards granted ethical approval: Johns 
Hopkins Bloomberg School of Public Health, USA; Hospital Universitario Japonés, Bolivia; Universidad Católica 
Boliviana, Bolivia; Universidad Peruana Cayetano Heredia, Peru; Asociación Benéfica Proyectos en Informatica, 
Salud, Medicina y Agricultura, Peru; and the Centers for Disease Control and Prevention, USA.
Gambian malaria sera were provided, with consent for further research on diagnostics, from London School 
of Hygiene and Tropical Medicine archives.
Non-endemic control sera were provided at the London School of Hygiene and Tropical Medicine and used 
with consent for further research on diagnostics.
Sources of chagasic sera. Chagasic sera were generously provided from the following sources: Colombia 
(Medellín, n = 55; Bogotá, n = 31); Ecuador (n = 14); Venezuela (n = 4), Peru (n = 42) and Bolivia (n = 10).
Assessing serological recognition of synthetic peptides by ELISA. Colombian (Medellín) sera 
were assayed by ELISA with synthetic peptides TSSApep-I, -II/V/VI, -III, -IV, -V/VI, according to protocols 
described  previously19. Colombian (Bogotá), Ecuadorean and Venezuelan sera were previously assayed with 
synthetic peptides TSSApep-I, -II/V/VI, -III, -IV, -V/VI by ELISA; all were negative with TSSApep-I19; Peruvian 
and Bolivian sera were previously assayed by TSSApep-II/V/VI  RDT22.
Prediction of glycosylation sites within gTSSA‑I recombinant. In order to determine the presence 
of O and N glycosylation sites on the TSSA-I epitope, the amino acid sequence was submitted to NetOGlyc 4.0 
(www.cbs.dtu.dk/services/NetOGlyc/) and NetNGlyc 1.0 (www.cbs.dtu.dk/servi ces/NetNG lyc/) online servers. 
Prediction included coverage of the SUMO component of gTSSA-I.
L. tarentolae production of recombinant antigens gTSSA‑I and gTSSA‑II/V/VI. The TSSA-
specific sequences were cloned into separate expression plasmids pLEXSY_I-blecherry3 with an upstream His 
tag and SUMO fusion partner to aid solubility of the resulting recombinant proteins, hereafter called gTSSA-I 
or gTSSA-II/V/VI, expressed in the L. tarentolae system (Jena Biosciences, Germany). Figure 1a,b depict the 
sequences of these recombinant antigens, with N-terminal histidine tag (blue), SUMO sequence (green) and 
TSSA-I sequence (red).
3Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16395  | https://doi.org/10.1038/s41598-020-73390-9
www.nature.com/scientificreports/
Production of recombinant protein, based on the methodology of Rooney et al.29 was carried out in 1 L 
baffled Erlenmeyer flasks in BHI medium (supplemented with antibiotics and hemin) and the medium was 
harvested when the  OD600 reached 4 (approx. 70 h post inoculation,  108 cells/ml). All media components were 
from Jena Bioscience. Clarified medium was concentrated 20- fold on a Pellicon XL 50 Ultrafiltration cassette 
(10 kDa MWCO) and diluted four times in binding buffer (20 mM Phosphate, 500 mM NaCl, 10 mM Imidazole) 
before addition to an equilibrated His Trap (GE Healthcare) FPLC column. Bound proteins were eluted using an 
increasing Imidazole gradient (20 mM Phosphate, 500 mM NaCl, 500 mM Imidazole). Peak protein containing 
fractions, as determined by  A280 nm measurement, were combined, desalted and concentrated by centrifugation 
in Amicon Ultra-15 device (5 kDa MWCO). Purified recombinant gTSSA-I was run on Coomassie blue-stained 
pre-cast 4–12% BisTris gradient SDS-PAGE gel (Novex) using the MOPS running system, along with Precision 
Plus Protein Unstained Standards (BioRad). The final protein was stored at 1 mg/ml in solution in PBS, 15% 
glycerol at – 20 °C.
Glycoproteomics. For glycoproteomics 20 µg of the glycoprotein with the gTSSA-I epitope were denatur-
ated in 10 µL 8 M guanidine hydrochloride solution and reduced with 1 µL of 10 mM DTT (Thermo Fisher 
Scientific) in 50 mM ammonium bicarbonate buffer (pH 8.4) for 30 min at 56 °C. 1 µL of 55 mM iodoacetamide 
(Thermo Fisher Scientific) was added and incubated at room temperature for 30 min in the dark. Finally, the 
digest was diluted with 30 µl of 50 mM ammonium bicarbonate buffer prior to adding 1 µL of trypsin (1:20 w/w 
enzyme:protein ratio).
The online ESI-LC–MS data were recorded in MSE mode for 60 min using a Waters Synapt G2 mass spectrom-
eter (Waters, Milford, MA). Separations were achieved on C18 Acquity UPLC M-Class column (HSS T3 1.8 µm 
75 µm × 150 mm) equilibrated at 40 °C. The mobile phases were A: 0.1% (v/v) formic acid (Biosolve Chemicals) 
in LC–MS grade water (Greyhound) and B: 0.1% (v/v) formic acid (Biosolve Chemicals) in acetonitrile (Grey-
hound). Lockmass was set to m/z: 785.80 Glu-1-Fibrinopeptide B (200 nmol/µl, Waters). The Synapt G2-S mass 
range was operated between 50–2000 m/z.
Initial peptide mapping was carried out using BiopharmaLynx 1.3.3 (Waters, Milford, MA) to locate the 
epitope region of the gTSSA-I construct in the chromatogram. Interpretations of glycopeptide MS data were 
Figure 1.  T. cruzi TSSA recombinant proteins produced in L. tarentolae expression system. (a) gTSSA-I 
protein sequence (based on GenBank GU059925) and (b) gTSSA-II/V/VI protein sequence (based on GenBank 
GU075675): histidine tag (blue), SUMO sequence (green), linker sequences (black) and TSSA sequences 
(red). Dots: Residues predicted to be O-glycosylated. Starred: Ser residue present in native TSSA-II/V/VI but 
absent in native TSSA-I. Underlined: lineage-specific polymorphic residues. (c) Predicted likelihood scores 
for O-glycosylation of TSSA-I sequence range between 0 (least)—1 (highest); scores below 0.5 not listed. (d) 
Coomassie blue stained gel of purified gTSSA-I.
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performed manually by previously reported methods based on amino acid and sugar masses together with the 
known fragmentation of  glycopeptides30, with the assistance of MassLynxV4.1. (Waters, Milford, MA).
Assessing serological efficacy of the recombinant antigen gTSSA‑I. Separate wells of a 96-well 
flat bottomed ELISA plates (735–0465: Immulon 4HBX, VWR) were coated with 50 μl/well of 1 µg/ml L. taren-
tolae-expressed gTSSA-I, and with 100 μl/well of 2 µg/ml lysate of T. cruzi TcII strains IINF/PY/00/Chaco23 
or MHOM/BR/00/Y in coating buffer (15 mM  Na2CO3, 34 mM  NaHCO3, pH 9.6). Lysates were prepared as 
described  previousy19. After overnight incubation at 4 °C, plates were washed three times with PBS/0.05% (v/v) 
Tween 20 (P7949: Sigma Aldrich, UK) (PBST), then blocked with 200 μl of PBS/2% skimmed milk powder 
(PBSM) at 37 °C for 2 h. Following three washes, 100 μl of 1:200 dilutions of serum in PBSM with 0.05% Tween 
20 (PBSMT) was applied and incubated at 37 °C for 1 h; after six further washes, 100 μl of donkey anti-human 
IgG (H + L)-HRP (709–035–149: Jackson ImmunoResearch, USA) diluted 1:2000 (Peruvian and Bogotá sera) 
or 1:4000 (Medellín, Ecuadorean, Venezuelan, Bolivian sera) in PBSMT was added and incubated at 37 °C for 
1 h. Following six washes, wells were developed with 100 µl/well of 50 mM phosphate/citrate buffer (pH 5.0) 
containing 2 mM o-phenylenediamine HCl (P1526: Sigma Aldrich) and 0.005% (vol/vol)  H2O2 (216763: Sigma 
Aldrich); the plates were incubated in the dark at room temperature for approximately 10 min. Reactions were 
stopped by 50  µl/well of 2  M  H2SO4, and absorbance values read at a wavelength of 490  nm. For Gambian 
malaria samples, sera were used at 1:100 and anti-human IgG 1:2000.
Excluding cross reaction with the SUMO component of recombinant antigens. A subset of 34 
Colombian (Medellín) samples were assayed for serological cross reactivity with the SUMO component of the 
recombinant antigens. This was done by parallel performance of ELISAs, as described above, with the recombi-
nant antigen gTSSA-II/V/VI coated in separate wells from the gTSSA-I.
Assessing the contribution of glycosylation and secondary structure to antigenicity of 
gTSSA‑I. Contribution of glycosylation to antigenicity was assessed using an assay based on the protocol 
of Woodward et al.31, and employed  subsequently32,33, which described the oxidative cleavage of carbohydrate 
vicinal –OH groups and subsequent reduction of generated aldehyde groups to prevent non-specific antibody 
binding. After the blocking and washing steps of the ELISA, described above, all wells were rinsed in periodate 
buffer (50 mM sodium acetate buffer, pH 4.5), and the wells that had been coated with gTSSA-I received 5 mM 
freshly-made sodium (meta)periodate (71859: Sigma Aldrich) in periodate buffer; the remaining wells received 
periodate buffer only. Plates were incubated in the dark at room temperature for 1 h, followed by rinsing of all 
wells with periodate buffer. The periodate-treated wells were then reduced with freshly-made 50 mM sodium 
borohydride (71320: Sigma Aldrich) in PBS for 30 min; the remaining wells received PBS only. Following this 
step, wells were washed three times with PBST before addition of sera and subsequent processing, as described 
above.
To investigate the contribution of secondary structure to the antigenicity of gTSSA-I, an aliquot of gTSSA-I 
in coating buffer was heated > 95 °C for up to 10 min, prior to coating onto the plate and performance of the 
serological efficacy was assessed as described above.
Statistical analysis. Replica ELISA plates were run in duplicate simultaneously. Cut-off values were deter-
mined by first subtracting the background absorbance values (i.e., mean of wells with coating buffer only, no 
antigen) from the mean reading for each sample; samples that were then greater than three standard deviations 
above the mean of seronegative non-endemic controls were considered positive. P values were determined by 
performing two-sample T test either unpaired (gTSSA-I against gTSSA-II/V/VI) or paired (unmodified gTSSA-I 
against oxidised or denatured) with GraphPad Prism (GraphPad Software, San Diego, USA).
Results
Synthetic peptides were not recognised by TcI endemic chagasic sera. All Colombian (Medellín 
and Bogotá), Ecuadorean, Venezuelan, and northern Peruvian sera samples (n = 146) were from regions consid-
ered to be endemic for TcI  principally11, and were predominantly from chronic cases of Chagas disease in rural 
 locations1,34. All sera were seropositive with T. cruzi lysate; (TcII and TcI lysate antigens do not discriminative 
between lineage infections). Apart from Colombia (Medellín) and Peruvian samples, all had been previously 
assayed with synthetic peptide TSSApep-I, and no reaction had been  identified19. Here, there was no TSSApep-
I recognition by the Colombian sera (Medellín) and no indication of the presence of infection with any of the 
other synthetic peptides.
Glycosylation prediction. Figure 1c shows the bioinformatic analysis predicting the likelihood score for 
O-linked glycosylation of the TSSA-I sequence used in gTSSA-I. No N-linked glycosylation was predicted by 
NetNGlyc 1.0, nor was any glycosylation predicted on the SUMO component of the recombinant proteins.
Recombinant antigens produced in L. tarentolae: gTSSA‑I and gTSSA‑II/V/VI. Recombinant 
proteins were produced by the L. tarentolae LEXSY system and purified by NiNTA from the culture media. The 
predicted mass is 15 kDa but a broad smear between 25 and 35 kDa is typical for a glycosylated protein (Fig. 1d, 
and supplementary Figure S1).
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Mass spectrometry analysis proves glycosylation of recombinant gTSSA‑I. Confirmation of 
glycosylation was demonstrated by mass spectrometry based glycoproteomics. An O-glycosylated glycopeptide 
was identified, consisting of the sequence TAA GGT PSPSGASSG substituted with a single N-acetylhexosamine 
(HexNAc) residue (Supplementary Figure S2). Such O-glycosylation with a single HexNAc residue is consistent 
with previous reports of L. tarentolae recombinant glycoprotein glycosylation, confirming the prediction of the 
NetOGlyc 4.0  programme28. As predicted by NetNGlyc 1.0, no N-linked glycosylation was found.
Recognition of gTSSA‑I. Overall (74/146; 50.7%) of chagasic sera from TcI endemic regions of northern 
South America were seropositive with gTSSA-I (Table 1).
Absence of SUMO cross‑reactivity between gTSSA‑I and gTSSA‑II/V/VI. A subset of Colombian 
(Medellín) sera positive for gTSSA-I (n = 34) were assayed by ELISA against gTSSA-II/V/VI, to assess levels of 
potential cross-reactivity to the SUMO component of gTSSA-I. No recognition of gTSSA-II/V/VI was observed 
with these sera (Fig. 2a). Grouping these data, there was a significant difference in the absorbance values between 
these two recombinant antigens (P < 0.0001) (Fig. 2b). Thus, there was no cross reactivity between these two 
recombinant antigens attributable to antibody recognition of the SUMO component. Bolivian sera shown previ-
ously to be reactive with synthetic peptide TSSApep-II/V/VI (n = 5) reacted with gTSSA-II/V/VI; two sera also 
recognising gTSSA-I (Fig. 2c), suggesting TcII/V/VI and TcI co-infection.
gTSSA‑I antigenicity is principally dependent on glycosylation, not structure. A subset of 
Colombian (Medellín) samples that recognised gTSSA-I (n = 12) were assayed against periodate-treated, heat 
denatured and unmodified gTSSA-I on the same ELISA plates. Recognition of gTSSA-I decreased substantially 
after periodate treatment, compared to the heat denatured antigen, for all samples except sample 2 (Fig. 3a). 
The absorbance values were significantly lower (P = 0.0002) after periodate treatment, with only a single sample 
retaining the same level of recognition as with the unmodified antigen. After heat denaturation the absorbance 
values of all 12 samples were reduced to a much lesser extent, albeit with a significant difference (P < 0.0001) 
(Fig. 3a).
gTSSA‑I recognition by some Gambian malaria sera is dependent on structure. Unexpectedly, 
recognition of gTSSA-I was observed with 13/24 Gambian malaria sera samples. Eight of these reactive samples 
were assayed against periodate-treated (oxidised) and heat denatured gTSSA-I. Oxidation had little effect on 
recognition of gTSSA-I, with no significant difference between absorbance values (P = 0.5732) and recognition 
of gTSSA-I was retained by all 8 samples. However, this was abolished by heat denaturation of this antigen 
(P = 0.0089). One sample remained above the cut-off, though the absorbance value had been greatly reduced 
(Fig. 3b,c). Any recognition of gTSSA-I by non-endemic healthy controls (NEHC) was also abrogated by heat-
denaturation.
Discussion
Lineage-specific serology for T. cruzi infections provides a powerful tool for understanding the epidemiology 
and ecology of Chagas disease. Here, we have investigated lineage-specific epitopes to determine the importance 
of glycosylation in antigen recognition, particularly in relation to TcI.
The L. tarentolae expression system has been used previously to produce Trypanosoma brucei gambiense 
surface antigens, as a low cost alternative to harvesting diagnostic antigens from T. b. gambiense grown in vitro29. 
Expression in L. tarentolae has also been applied in attempts to improve diagnostic antigens for the trypanoso-
matids Leishmania braziliensis35 and Leishmania donovani36.
Here, we applied L. tarentolae expression to produce recombinant T. cruzi gTSSA-I, and to determine whether 
consequent glycosylation or more bona fide structural conformation of the protein conferred serological rec-
ognition upon the antigen.
All Colombian, Venezuelan, and Ecuadorean sera that were positive here with gTSSA-I were previously 
seronegative with the synthetic peptide TSSApep-I. The Medellín samples showed by far the highest proportion 
that recognised gTSSA-I; 85.5%. Reasons for this are unclear, but may be related to lower levels of anti-T. cruzi 
IgG in the other sera; in some localities there are low IgG antibody levels in T. cruzi  infections37. Furthermore, 
the gTSSA-I positive samples were not seropositive with gTSSA-II/V/VI, demonstrating that there was no sero-
logical cross reaction with the SUMO component of the recombinant antigens. Thus, we have demonstrated 
Table 1.  Recognition of gTSSA-I by chagasic sera from northern South America.
Source gTSSA-I reactive (%)
Colombia (Medellín) 47/55 (85.5%)
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clear, robust TcI lineage-specific serology with sera originating from countries where TcI has been identified by 
genotyping as the principal cause of Chagas disease.
In comparison with synthetic peptides or production of recombinants in the bacterium E. coli, heterologous 
expression in the eukaryote L. tarentolae enables glycosylation of the trypanosomatid proteins and adoption of 
a more natural conformation. O- and N-linked glycosylation of recombinant proteins in L. tarentolae has been 
described, and the wild type pattern in T. cruzi also shown to be O-linked (GlcNAc)28,38. Assays with periodate-
treated antigen showed that the protein glycosylation (predicted by the online algorithms and demonstrated by 
glycoproteomics), and not the protein conformation, was important for serological recognition of gTSSA-I. Thus, 
expression in L. tarentolae revealed antigenic properties of TSSA-I that are not evident in synthetic peptides or 
E. coli-expressed recombinant proteins.
The specificity of gTSSA-I was questioned, due to some cross-reactivity with non-endemic (Gambian) malaria 
control sera. The sera from malaria were included due to breadth of immune response associated with anti-
genic variation, and recent research interest in whether antibodies to Plasmodium may recognise glycosylated 
 antigens39. Two of these controls were also seropositive with the lateral flow diagnostic test specifically to detect 
exposure to T. b. gambiense infection (data not shown), suggesting an explanation for their cross reactivity. 
However, heating gTSSA-I abolished recognition by all Gambian malaria sera, demonstrating that this was 
due to analogous protein structure of gTSSA-I, not glycosylation. Since this is contrary to gTSSA-I recognition 
by chagasic sera, heating of gTSSA-I prior to performance of diagnostic ELISA or to incorporation into RDTs 
provides TcI-specific diagnosis via recognition of glycosylation antigenicity.
We have previously demonstrated a link between serological recognition of TSSApep-II/V/VI and severity 
of chagasic cardiac  symptoms19,22. Availability of gTSSA-I serology enables parallel investigation of clinical sta-
tus associated with TcI infection, and serological detection of sporadic TcII/V/VI and TcI co-infections, which 
occur in some Bolivian and Brazilian endemic  foci40,41. As with application of TSSA-II/V/VI serology to sylvatic 
Figure 2.  Antigenicity of gTSSA-I is due to TSSA-I sequence. (a) Absorbance values with Colombian 
(Medellín) sera recognising gTSSA-I (blue bars) and gTSSA-II/V/VI (orange bars). (b) Overall absorbance 
values for Colombian (Medellín) sera against gTSSA-I (blue) and gTSSA-II/V/VI (orange); gTSSA-I is 
recognised, whereas gTSSA-II/V/VI is not (P < 0.0001). (c) ELISA plate illustrating the recognition of gTSSA-I 
but not of gTSSA-II/V/VI; all samples were seropositive with lysate, and coating buffer controls were negative. 
Sample numbers correspond with (a). Positive control: serum from a Bolivian patient previously shown to be 
reactive with synthetic peptide TSSApep-II/V/VI and also seropositive with gTSSA-I, indicating co-infection 
(see text).
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 mammals20,21,23,42,43, gTSSA-I can be deployed for resolution of TcI domestic and sylvatic transmission cycles, 
and for discovery of reservoir hosts. Thus, expression of L. tarentolae recombinant antigens representing epitopes 
specific to each of the T. cruzi lineages, may facilitate comprehensive epidemiological investigations. Our results 
encourage L. tarentolae expression to improve efficacy of candidate diagnostic antigens.
Proteins have been preferentially pursued for decades as highly sensitive and specific diagnostic antigens, and 
as vaccine candidates. Perhaps most importantly, as recognised in recent research on  malaria39 and  bacteria44 we 
have indicated here that glycosylation cannot be ignored in the search for improved diagnostics or efficacious 
vaccines.
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